b-rayZ AG: Company Research Report

Company Overview

Name

b-rayZ AG

Mission

To make breast cancer less of a threat for women worldwide through innovative AI solutions and advanced breast imaging technology.

Founding and Founders

Founded by:

Prof. Dr. Cristina Rossi

PD. Dr. Alexander Ciritsis

Prof. Dr. med. Andreas Boss

Key People

Prof. Dr. Cristina Rossi: Co-Founder and CEO

PD. Dr. Alexander Ciritsis: Co-Founder and CTO

Prof. Dr. med. Andreas Boss: Co-Founder and Medical Advisor

Béatrice Fink: CFO, Strategic Partnerships

Philippe Pech: CSO, Business Development

Harry Welten: Chairman of the Board

Headquarters

Zurich, Switzerland

Number of Employees

No information is available

Revenue

No information is available

Known For

State-of-the-art AI technology for breast imaging

Improving early breast cancer detection and patient outcomes

Comprehensive AI-driven breast imaging ecosystem

Products

Offerings

b-rayZ offers a comprehensive AI-powered platform for breast cancer diagnostics, known for its efficient, accurate, and sustainable diagnostic processes.

Key Products:

1. b-density

Description: Provides real-time ACR breast density classification.

Features: Optimized for tomosynthesis and mammography, offers standardized recommendations for supplemental ultrasound exams with 90% accuracy.

2. b-quality

Description: Enhances mammogram quality.

Features: Reduces patient recalls and aligns with interpreting physician assessments with high accuracy.

3. b-smart

Description: Performance monitoring dashboard.

Features: Enables lean resource management and procedural optimization.

4. b-diagnose

Description: Complete radiological analysis.

Features: Generates BI-RADS compliant reports aiding decision making in lesion management.

5. b-risk

Description: Risk assessment module.

Features: Provides risk scores for early detection and personalized screening plans set for late 2024 release.

Product Features

Seamless integration with existing IT infrastructure.

CE Mark, ISO13485, and Swiss Made Software accredited.

Robust analytics and real-time feedback to optimize workflow.

Recent Developments

Recent Developments in the Company

Selected as AI provider for Geneva Trust: Enhanced mammography screening in Poland (Oct 10, 2024).

Digital Economy Award 2024 Finalist: Recognized in the "Next Global Hot Thing – in AI" category (Sep 10, 2024).

Partnership with Healthcare Konnect (HCK): Extended to North Africa, aiming to improve breast cancer detection (Jun 06, 2024).

Appointment of Harry Welten: As Chairman of the Board enhancing strategic leadership (Jun 03, 2024).

New Products and Features

Expansion of AI Platform: Continual development of modules like b-risk expected in late 2024.

Live Demonstrations: Showcased AI innovations at various international conferences.

Integrations and Accreditations: Achieved new partnerships for the integration of customized AI solutions into healthcare systems.

New Partnerships

Geneva Trust Polska: To improve breast cancer screening accuracy in Poland.

Healthcare Konnect (HCK): For expanded AI diagnostic applications in North Africa.

Conclusion

b-rayZ AG stands at the forefront of breast imaging technology by leveraging Swiss medical expertise and AI-driven solutions to enhance the accuracy and efficiency of breast cancer diagnostics globally. With a focus on integrating advanced AI tools within clinical workflows, the company is set to transform patient care while establishing strong partnerships to broaden its impact on women's health.